Valsartan ameliorates KIR2.1 in rats with myocardial infarction via the NF-κB-miR-16 pathway

miR-16 controls KCNJ2 expression, and valsartan ameliorates Kir2.1 after MI partly depending on the NF-κB-miR-16 pathway.